Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E A Stadtmauer

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Blood|July 15, 1995
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)J M Rowe, J W Andersen, J J Mazza, et al.
Gynecologic Oncology|January 27, 1998
Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancerM A Morgan, E A Stadtmauer, S M Luger, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 12, 2011
Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)R Reshef, S Vardhanabhuti, M R Luskin, et al.
Transplantation|May 26, 2001
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patientsD E Tsai, C L Hardy, J E Tomaszewski, et al.
Leukemia|July 24, 2009
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaM A Dimopoulos, C Chen, A Spencer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2001
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantationD L Porter, S M Luger, K M Duffy, et al.
Bone Marrow Transplantation|April 28, 2010
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimenA Nazha, R Cook, D T Vogl, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 14, 2006
Treatment of PTLD with rituximab or chemotherapyR L Elstrom, C Andreadis, N A Aqui, et al.
The New England Journal of Medicine|April 13, 2000
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant GroupE A Stadtmauer, A O'Neill, L J Goldstein, et al.
Bone Marrow Transplantation|October 14, 2008
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaR L Olin, D T Vogl, D L Porter, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Blood|July 15, 1995
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)J M Rowe, J W Andersen, J J Mazza, et al.
Gynecologic Oncology|January 27, 1998
Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancerM A Morgan, E A Stadtmauer, S M Luger, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 12, 2011
Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)R Reshef, S Vardhanabhuti, M R Luskin, et al.
Transplantation|May 26, 2001
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patientsD E Tsai, C L Hardy, J E Tomaszewski, et al.
Leukemia|July 24, 2009
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaM A Dimopoulos, C Chen, A Spencer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2001
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantationD L Porter, S M Luger, K M Duffy, et al.
Bone Marrow Transplantation|April 28, 2010
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimenA Nazha, R Cook, D T Vogl, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 14, 2006
Treatment of PTLD with rituximab or chemotherapyR L Elstrom, C Andreadis, N A Aqui, et al.
The New England Journal of Medicine|April 13, 2000
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant GroupE A Stadtmauer, A O'Neill, L J Goldstein, et al.
Bone Marrow Transplantation|October 14, 2008
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaR L Olin, D T Vogl, D L Porter, et al.
Pageof 6